Manuscripts and Publications
Filters: Author is Wilson, Craig M [Clear All Filters]
.
2013. The acceptability and feasibility of an HIV preexposure prophylaxis (PrEP) trial with young men who have sex with men.. J Acquir Immune Defic Syndr. 62(4):447-56.
.
2016. Antiretroviral treatment initiation does not differentially alter neurocognitive functioning over time in youth with behaviorally acquired HIV.. J Neurovirol. 22(2):218-30.
.
2013. Assessment of biomarkers of cardiovascular risk among HIV type 1-infected adolescents: role of soluble vascular cell adhesion molecule as an early indicator of endothelial inflammation.. AIDS Res Hum Retroviruses. 29(3):493-500.
.
2013. Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency? Antimicrob Agents Chemother. 57(11):5619-28.
.
2019. Brief Report: Role of Sociobehavioral Factors in Subprotective TFV-DP Levels Among YMSM Enrolled in 2 PrEP Trials.. J Acquir Immune Defic Syndr. 80(2):160-165.
.
2007. Calibration and validation of an oral fluid-based sensitive/less-sensitive assay to distinguish recent from established HIV-1 infections.. J Clin Lab Anal. 21(1):40-5.
.
2020. Changes in Bone Mass After Discontinuation of Preexposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine in Young Men Who Have Sex With Men: Extension Phase Results of Adolescent Trials Network Protocols 110 and 113.. Clin Infect Dis. 70(4):687-691.
.
2009. Clear and independent associations of several HLA-DRB1 alleles with differential antibody responses to hepatitis B vaccination in youth.. Hum Genet. 126(5):685-96.
.
2018. Comparison of Measures of Adherence to Human Immunodeficiency Virus Preexposure Prophylaxis Among Adolescent and Young Men Who Have Sex With Men in the United States.. Clin Infect Dis. 66(2):213-219.
.
2013. Comprehension of a simplified assent form in a vaccine trial for adolescents.. J Med Ethics. 39(6):410-2.
.
2021. Cost-effectiveness of Frequent HIV Screening Among High-risk Young Men Who Have Sex With Men in the United States.. Clin Infect Dis. 73(7):e1927-e1935.
.
2018. A cross-sectional study examining associations between substance use frequency, problematic use and STIs among youth living with HIV.. Sex Transm Infect. 94(4):304-308.
.
2017. Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.. Clin Infect Dis. 64(3):317-325.
.
2010. Demographic profiles of newly acquired HIV infections among adolescents and young adults in the U.S.. J Adolesc Health. 46(1):93-6.
.
2016. Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing.. Antimicrob Agents Chemother. 60(11):6692-6697.
.
2017. Evaluating Testing Strategies for Identifying Youths With HIV Infection and Linking Youths to Biomedical and Other Prevention Services.. JAMA Pediatr. 171(6):532-537.
.
2013. Genetic associations with 25-hydroxyvitamin D deficiency in HIV-1-infected youth: fine-mapping for the GC/DBP gene that encodes the vitamin D-binding protein.. Front Genet. 4:234.
.
2018. HIV Continuum of Care for Youth in the United States.. J Acquir Immune Defic Syndr. 77(1):110-117.
.
2017. An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM.. J Acquir Immune Defic Syndr. 74(1):21-29.
.
2006. HIV-1 epitope-specific CD8+ T cell responses strongly associated with delayed disease progression cross-recognize epitope variants efficiently.. J Immunol. 176(10):6130-46.
.
2015. Immune Reconstitution but Persistent Activation After 48 Weeks of Antiretroviral Therapy in Youth With Pre-Therapy CD4 >350 in ATN 061.. J Acquir Immune Defic Syndr. 69(1):52-60.
.
2013. Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women.. Clin Infect Dis. 57(5):735-44.
.
2007. Immunological control of chronic HIV-1 infection: HLA-mediated immune function and viral evolution in adolescents.. AIDS. 21(18):2387-97.
.
2017. Implementation of an Integrated Approach to the National HIV/AIDS Strategy for Improving Human Immunodeficiency Virus Care for Youths.. JAMA Pediatr. 171(7):687-693.
.
2008. Inclusion of adolescents in preventive HIV vaccine trials: public health policy and research design at a crossroads.. J Acquir Immune Defic Syndr. 47(1):86-92.
.
2018. Linking HIV-Negative Youth to Prevention Services in 12 U.S. Cities: Barriers and Facilitators to Implementing the HIV Prevention Continuum.. J Adolesc Health. 62(4):424-433.
.
2012. Low bone mass in behaviorally HIV-infected young men on antiretroviral therapy: Adolescent Trials Network Study 021B.. Clin Infect Dis. 55(3):461-8.
.
2010. Obesity and dyslipidemia in behaviorally HIV-infected young women: Adolescent Trials Network study 021.. Clin Infect Dis. 50(1):106-14.
.
2018. Partner Notification for Youth Living With HIV in 14 Cities in the United States.. J Acquir Immune Defic Syndr. 77(1):46-52.
.
2008. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.. Antimicrob Agents Chemother. 52(2):631-7.
.
2019. Pre-vaccination prevalence of anogenital and oral human papillomavirus in young HIV-infected men who have sex with men.. Papillomavirus Res. 7:52-61.
.
2012. Prevalence and risk factors for HPV in HIV-positive young women receiving their first HPV vaccination.. J Acquir Immune Defic Syndr. 61(3):390-9.
.
2006. Prevalence of primary HIV-1 drug resistance among recently infected adolescents: a multicenter adolescent medicine trials network for HIV/AIDS interventions study.. J Infect Dis. 194(11):1505-9.
.
2012. Prevalence of proteinuria and elevated serum cystatin C among HIV-Infected Adolescents in the Reaching for Excellence in Adolescent Care and Health (REACH) study.. J Acquir Immune Defic Syndr. 61(4):499-506.
.
2020. Prior incarceration associated with missed HIV care visits among young people living with HIV in the US.. AIDS Care. 32(9):1150-1154.
.
2010. Randomized trial to determine safety and immunogenicity of two strategies for hepatitis B vaccination in healthy urban adolescents in the United States.. Pediatr Infect Dis J. 29(6):530-4.
.
2015. Rates and correlates of antiretroviral therapy use and virologic suppression among perinatally and behaviorally HIV-infected youth linked to care in the United States.. J Acquir Immune Defic Syndr. 68(2):169-77.
.
2018. The role of socio-behavioral factors in sub-protective tenofovir diphosphate (TFV-DP) levels among YMSM enrolled in two PrEP trials.. J Acquir Immune Defic Syndr.
.
2017. Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States.. JAMA Pediatr. 171(11):1063-1071.
.
2012. Serum 25-hydroxyvitamin D response to vitamin D3 supplementation 50,000 IU monthly in youth with HIV-1 infection.. J Clin Endocrinol Metab. 97(11):4004-13.
.
2016. Sexual Risk Behavior Among Virologically Detectable Human Immunodeficiency Virus-Infected Young Men Who Have Sex With Men.. JAMA Pediatr. 170(2):125-31.
.
2009. Short-cycle therapy in adolescents after continuous therapy with established viral suppression: the impact on viral load suppression.. AIDS Res Hum Retroviruses. 25(6):555-61.
.
2012. Substantial multiclass transmitted drug resistance and drug-relevant polymorphisms among treatment-naïve behaviorally HIV-infected youth.. AIDS Patient Care STDS. 26(4):193-6.
.
2018. Tenofovir disoproxil fumarate appears to disrupt the relationship of vitamin D and parathyroid hormone.. Antivir Ther. 23(7):623-628.
.
2018. Tobacco Use and Sustained Viral Suppression in Youth Living with HIV.. AIDS Behav. 22(6):2018-2025.
.
2006. Vitamin D status in adolescents and young adults with HIV infection.. Am J Clin Nutr. 83(5):1135-41.
.
2012. Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial.. Clin Infect Dis. 54(7):1013-25.
.
2014. Vitamin D3 supplementation increases fibroblast growth factor-23 in HIV-infected youths treated with tenofovir disoproxil fumarate.. Antivir Ther. 19(6):613-8.